Replies to post #53202 on Biotech Values

[DewDiligence]

HCV maintenance therapy for non-responders:

SGP will present data from such a study at AASLD next week. The doses of PegIntron and ribavirin are lower than they are for standard HCV treatment, but the company hasn’t yet said how much lower.

http://biz.yahoo.com/prnews/071030/nytu018b.html?.v=2